This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drews, S. J.
Right arrow Articles by Low, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drews, S. J.
Right arrow Articles by Low, D. E.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2005, p. 4218-4220, Vol. 43, No. 8
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.8.4218-4220.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Decreased Prevalence of Virulence Factors among Ciprofloxacin-Resistant Uropathogenic Escherichia coli Isolates

S. J. Drews,1,2 S. M. Poutanen,1,2 T. Mazzulli,1,2 A. J. McGeer,1,2 A. Sarabia,3 S. Pong-Porter,1 Y. Rzayev,1 B. Willey,1 K. Green,1 and D. E. Low1,2*

Toronto Medical Laboratories & Mount Sinai Hospital, Toronto, Ontario, Canada,1 University of Toronto, Toronto, Ontario, Canada,2 MDS Laboratories, Toronto, Ontario, Canada3

Received 12 January 2005/ Returned for modification 28 February 2005/ Accepted 25 April 2005


arrow
ABSTRACT
 
Ciprofloxacin resistance was identified in 18% and 6% of consecutively collected, clinically significant urinary tract isolates of Escherichia coli from inpatients and outpatients, respectively. In comparison to ciprofloxacin-susceptible isolates, there were fewer resistant isolates that expressed beta-hemolysis (outpatient, 9% versus 87%, P < 0.0001; inpatient, 4% versus 76%, P < 0.0001) and that had a papEF genotype, genes encoding P fimbriae (outpatient, 30% versus 70%, P = 0.0004; inpatient, 26% versus 70%, P < 0.0001).


arrow
TEXT
 
Escherichia coli is the principle cause of urinary tract infections in both community and hospital settings in North America. Two of the major uropathogenic virulence factors expressed by E. coli include a hemolysin protein and the mannose-resistant P fimbriae. Hemolysin assists in the acquisition of iron to regulate the expression of virulence factors (22). P fimbriae are encoded by a "pilus associated with pyelonephritis" pap operon which can be carried on one or more mobile genetic elements called pathogenicity-associated islands (PAIs) (22). This P fimbria construction requires both the tip association protein PapE (papE) and the tip protein PapF (papF) (7, 19), which then produce a receptor that binds to Gal{alpha}(1-4)Gal receptors on uroepithelial cells (14). This binding event prevents bacterial washout, breaks the mucosal barrier, and initiates the host immune response (2). We realize that there are a variety of other adhesins and virulence factors that are involved in uropathogenesis, and a subset of urinary tract infection isolates carry the Dr/Afa adhesins (3, 10). This study focuses on P fimbriae because (i) they may be the primary adherence factor isolated from uropathogenic isolates of E. coli (4, 28); (ii) they trigger the host immune response (2); and (iii) they fulfil Koch-Henle molecular postulates by conferring on an avirulent nonfimbriated strain the ability to induce a host response in the human urinary tract (30). Since a hemolysin and the P fimbriae are often associated on the same PAI (9, 22), we decided to use hemolysis as a phenotypic indicator for the presence of an island of pathogenicity that might carry genes encoding the P fimbriae.

Fluoroquinolones such as ciprofloxacin have been suggested as an effective empirical treatment for uncomplicated urinary tract infections with high levels (>10%) of resistance among uropathogens to trimethoprim-sulfamethoxazole or trimethoprim (29). However, some evidence indicates that increasing ciprofloxacin use may be associated with ciprofloxacin resistance (11). This concern about the development of ciprofloxacin resistance led us to address the prevalence of ciprofloxacin resistance in urinary tract isolates of E. coli. Recent evidence also indicates that resistance of E. coli to nalidixic acid may be associated with the loss of beta-hemolysis and P fimbria expression (25). The potential for linkage between fluoroquinolone resistance and the expression of virulence factor proteins prompted us to determine (i) the current levels of ciprofloxacin resistance in urinary tract isolates of E. coli in Ontario, Canada, and (ii) the prevalence of these virulence factors among fluoroquinolone-resistant and -susceptible isolates.

A private laboratory serving community physicians and clinics in southern Ontario and a hospital laboratory serving both secondary- and tertiary-care hospitals collected all isolates from patients with significant and reportable bacteriuria between November 2003 and February 2004 (24). Only one isolate per patient was included in our sample. Organisms were identified by conventional methodology. Susceptibility to ciprofloxacin and nalidixic acid was tested by broth microdilution using NCCLS criteria (18).

All ciprofloxacin-resistant isolates and randomly selected ciprofloxacin-susceptible isolates were screened for beta-hemolysis by culturing each on 5% sheep blood agar for 24 h at 35°C. In addition, all ciprofloxacin-resistant isolates and randomly selected ciprofloxacin-susceptible isolates were tested for the presence of papEF. All nalidixic acid-resistant isolates and a randomly chosen group of nalidixic acid-susceptible isolates were also tested for beta-hemolysis and papEF. papEF was detected using PCR as previously described (31). Primers for amplification of a 336-bp sequence spanning the papE and papF genes were designed as previously published, with the exception that bacterial cells were boiled in distilled water and centrifuged for 10 min at 15,000 x g at room temperature (15, 31). To verify the validity of negative results from PCRs, genomic bacterial DNA was isolated from each papEF-negative isolate by using a phenol-chloroform extraction protocol and quantified by using a spectrophotometer as previously described (1) and then reanalyzed by PCR. Negative samples were then spiked with DNA containing papEF to show that amplicon production could occur in the presence of a target gene and that each negative result was not due to technical problems. The identity of the amplicon was verified by restriction enzyme analysis with TacI per the manufacturer's protocol (Boehringer Mannheim, Germany). Following TacI digestion of PCR amplicons, the approximately 100-bp and 240-bp fragments were separated by agarose gel electrophoresis and visualized with ethidium bromide. Positive controls for this PCR included the uropathogenic strain E. coli CFT073 (22) (a gift from C. Gyles, University of Guelph, Guelph, Ontario, Canada). Nonuropathogenic E. coli BL-21 (Novagen, R&D, Madison, WI) was used as a negative control (23).

A total of 497 and 595 isolates were collected from outpatients and inpatients, respectively, over the study period. Among all urinary tract pathogens, E. coli was the most common, isolated with a frequency of 77% (n = 381) from outpatient isolates and 65% (n = 386) from inpatient isolates (18). The MICs of a variety of antibiotics were tested according to NCCLS guidelines (18). For outpatient isolates of E. coli, the frequencies of resistance to commonly tested antibiotics were as follows: cefazolin, 14 isolates (4%); cefprozil, 14 isolates (4%); amoxicillin-clavulinic acid, 17 isolates (4%); gentamicin, 5 isolates (1%); nitrofurantoin, 7 isolates (2%); ceftriaxone, 2 isolates (0.5%); and trimethoprim-sulfamethoxazole, 53 isolates (14%). For inpatient isolates of E. coli, the frequencies of resistance to commonly tested antibiotics were as follows: cefazolin, 26 isolates (7%); cefprozil, 36 isolates (9%); amoxicillin-clavulinic acid, 29 isolates (8%); gentamicin, 16 isolates (4%); nitrofurantoin, 8 isolates (2%); ceftriaxone, 3 isolates (0.8%); and trimethoprim-sulfamethoxazole, 82 isolates (21%). Resistance to ciprofloxacin and nalidixic acid was detected in 6% and 11%, respectively, of outpatient E. coli isolates and 18% and 21%, respectively, of inpatient E. coli isolates (Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Ciprofloxacin and nalidixic acid resistance in urinary tract isolates of E. coli from outpatients and inpatients

Beta-hemolysis was statistically significantly less likely in both outpatient and inpatient fluoroquinolone-resistant strains in this study than in fluoroquinolone-susceptible isolates (Tables 2 and 3). In addition, papEF was also statistically less likely in both the outpatient and inpatient fluoroquinolone-resistant strains than in fluoroquinolone-susceptible isolates (Tables 2 and 3). Similar findings were seen with the nalidixic acid-resistant isolates and the nalidixic acid-susceptible isolates. No statistical association was found between specific ciprofloxacin MICs in ciprofloxacin-resistant isolates and beta-hemolysis and papEF (data not shown), but the power to show such a difference was limited due to the small sample size.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Frequency of beta-hemolysis and papEF genotype in urinary tract isolates of E. coli from outpatients


View this table:
[in this window]
[in a new window]
  		TABLE 3. Frequency of beta-hemolysis and papEF genotype in urinary tract isolates of E. coli from inpatients

This study adds a new dimension to previous work showing that nalidixic acid-resistant uropathogenic E. coli isolates have a lower prevalence of beta-hemolysis and papEF than susceptible isolates (25). An important element separating this from previous work is that we have focused on ciprofloxacin, which, unlike nalidixic acid (17), is currently utilized in a twice-daily regime for uncomplicated urinary tract infections (26). Since ciprofloxacin is currently used in protocols to treat urinary tract infections, we feel that it is appropriate to develop a stronger understanding of the interaction between ciprofloxacin resistance and changes in virulence factor expression and genotype. Therefore, as ciprofloxacin use in urinary tract infections drives up the frequency of ciprofloxacin-resistant isolates of E. coli (11), clinicians may begin to see a modification in the patterns of urinary tract disease accompanied by changes in the expression of specific E. coli virulence factors.

Resistance to fluoroquinolones is largely mediated by point mutations in gyrase and topoisomerase (20, 21) but may be due to efflux and plasmid-mediated mechanisms (27). How fluoroquinolone resistance is linked to loss of beta-hemolysis and papEF is not obvious. It has been proposed that fluoroquinolone-resistant bacteria may be less fit than susceptible isolates due to decreased efficiency of gyrase and topoisomerase (5, 12). In contrast, the development of resistance to ampicillin has been correlated to the presence of the Dr adhesin, which plays a role in colonization and invasion of the host (6). Since we did not study ampicillin susceptibility, we cannot compare our results with those of Hart et al. (6). Loss of beta-hemolysis may be due to decreases in beta-hemolysin mRNA due to transcription-coupled DNA supercoiling (13). Loss of PAIs in the face of possible inhibition of gyrase or topoisomerase has been described previously (S. Soto, J. Mensa, T. Jimenez de Anta, and J. Vila, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. 82905, 2003); the driving force behind PAI loss may be a signal to escape a genome which is less fit to replicate.

Although ciprofloxacin-resistant E. coli isolates that are not beta-hemolytic and do not have papEF should be less able to be uropathogenic, ciprofloxacin resistance itself may be a virulence factor that allows for the survival of a bacterium within the urinary tract of ciprofloxacin-treated patients. In the future, it may be necessary to study the association between ciprofloxacin resistance and the loss of virulence factors, including other toxins (8) and other adhesion mechanisms (3), in E. coli. This future work will be enabled by the publication of a large number of primers designed to study these virulence factors using PCR (16, 31).


arrow
ACKNOWLEDGMENTS
 
S.J.D. was supported by a Clinical Microbiology Fellowship from the Ontario Government Ministry of Health and Longterm Care.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Toronto Medical Laboratories & Mount Sinai Hospital, Department of Microbiology, Room 1470, 600 University Avenue, Toronto, ON, Canada, M5G 1X5. Phone: (416) 586-4435. Fax: (416) 586-8746. E-mail: dlow{at}mtsinai.on.ca. Back


arrow
REFERENCES
 
    1
  1. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, K. Struhl, L. M. Albright, D. M. Coen, and A. Varki (ed.). 2002. Current protocols in molecular biology, p. 2.0.1-2.12.7. John Wiley and Sons, Inc., Indianapolis, Ind.
    2. 2
  2. Bergsten, G., M. Samuelsson, B. Wullt, I. Leijonhufvud, H. Fischer, and C. Svanborg. 2004. PapG-dependent adherence breaks mucosal inertia and triggers the innate host response. J. Infect. Dis. 189:1734-1742.[CrossRef][Medline]
    3. 3
  3. Blanco, M., J. E. Blanco, M. P. Alonso, A. Mora, C. Balsalobre, F. Munoa, A. Juarez, and J. Blanco. 1997. Detection of pap, sfa and afa adhesin-encoding operons in uropathogenic Escherichia coli strains: relationship with expression of adhesins and production of toxins. Res. Microbiol. 148:745-755.[Medline]
    4. 4
  4. Daigle, F., J. Harel, J. M. Fairbrother, and P. Lebel. 1994. Expression and detection of pap-, sfa-, and afa-encoded fimbrial adhesin systems among uropathogenic Escherichia coli. Can. J. Microbiol. 40:286-291.[Medline]
    5. 5
  5. Gillespie, S. H., L. L. Voelker, and A. Dickens. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 8:79-84.[CrossRef][Medline]
    6. 6
  6. Hart, A., B. J. Nowicki, B. Reisner, E. Pawelczyk, P. Goluszko, P. Urvil, G. Anderson, and S. Nowicki. 2001. Ampicillin-resistant Escherichia coli in gestational pyelonephritis: increased occurrence and association with the colonization factor Dr adhesin. J. Infect. Dis. 183:1526-1529.[CrossRef][Medline]
    7. 7
  7. Hoschützky, H., F. Lottspeich, and K. Jann. 1989. Isolation and characterization of the {alpha}-galactosyl-1,4-ß-galactosyl-specific adhesin (P adhesin) from fimbriated Escherichia coli. Infect. Immun. 57:76-81.[Abstract/Free Full Text]
    8. 8
  8. Island, M. D., X. Cui, B. Foxman, C. F. Marrs, W. E. Stamm, A. E. Stapleton, and J. W. Warren. 1998. Cytotoxicity of hemolytic, cytotoxic necrotizing factor 1-positive and -negative Escherichia coli to human T24 bladder cells. Infect. Immun. 66:3384-3389.[Abstract/Free Full Text]
    9. 9
  9. Johnson, J. R., C. E. Johnson, and J. N. Maslow. 1999. Clinical and bacteriologic correlates of the papG alleles among Escherichia coli strains from children with acute cystitis. Pediatr. Infect. Dis. J. 18:446-451.[CrossRef][Medline]
    10. 10
  10. Kachroo, B. B. 2001. Association between antibiotic resistance and the expression of Dr adhesin among uropathogenic Escherichia coli. Chemotherapy 47:97-103.[CrossRef][Medline]
    11. 11
  11. Kahlmeter, G., P. Menday, and O. Cars. 2003. Non-hospital antimicrobial usage and resistance in community-acquired Escherichia coli urinary tract infection. J. Antimicrob. Chemother. 52:1005-1010.[Abstract/Free Full Text]
    12. 12
  12. Kugelberg, E., S. Lofmark, B. Wretlind, and D. I. Andersson. 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 55:22-30.[Abstract/Free Full Text]
    13. 13
  13. Leng, F., L. Amado, and R. McMacken. 2004. Coupling DNA supercoiling to transcription in defined protein systems. J. Biol. Chem. 279:47564-47571.[Abstract/Free Full Text]
    14. 14
  14. Lund, B., F. Lindberg, and S. Normark. 1988. Structure and antigenic properties of the tip-located P pilus proteins of uropathogenic Escherichia coli. J. Bacteriol. 170:1887-1894.[Abstract/Free Full Text]
    15. 15
  15. Mohran, Z. S., R. R. Arthur, B. A. Oyofo, L. F. Peruski, M. O. Wasfy, T. F. Ismail, and J. R. Murphy. 1998. Differentiation of Campylobacter isolates on the basis of sensitivity to boiling in water as measured by PCR-detectable DNA. Appl. Environ. Microbiol. 64:363-365.[Abstract/Free Full Text]
    16. 16
  16. Morin, M. D., and W. J. Hopkins. 2002. Identification of virulence genes in uropathogenic Escherichia coli by multiplex polymerase chain reaction and their association with infectivity in mice. Urology 60:537-541.[CrossRef][Medline]
    17. 17
  17. Naber, K. G. 2001. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int. J. Antimicrob. Agents 17:331-341.[CrossRef][Medline]
    18. 18
  18. NCCLS. 2003. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, Pa.
    19. 19
  19. Oelschlaeger, T. A., U. Dobrindt, and J. Hacker. 2002. Virulence factors of uropathogens. Curr. Opin. Urol. 12:33-38.[CrossRef][Medline]
    20. 20
  20. Oethinger, M., I. Podglajen, W. V. Kern, and S. B. Levy. 1998. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob. Agents Chemother. 42:2089-2094.[Abstract/Free Full Text]
    21. 21
  21. Piddock, L. J. 1995. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 49(Suppl. 2):29-35.
    22. 22
  22. Rasko, D. A., J. A. Phillips, X. Li, and H. L. Mobley. 2001. Identification of DNA sequences from a second pathogenicity island of uropathogenic Escherichia coli CFT073: probes specific for uropathogenic populations. J. Infect. Dis. 184:1041-1049.[CrossRef][Medline]
    23. 23
  23. Sung, M. A., H. A. Chen, and S. Matthews. 2001. Sequential assignment and secondary structure of the triple-labelled carbohydrate-binding domain of papG from uropathogenic E. coli. J. Biomol. NMR 19:197-198.[CrossRef][Medline]
    24. 24
  24. Tan, J. S. 2002. Expert guide to infectious diseases. American College of Physicians, Philadelphia, Pa.
    25. 25
  25. Vila, J., K. Simon, J. Ruiz, J. P. Horcajada, M. Velasco, M. Barranco, A. Moreno, and J. Mensa. 2002. Are quinolone-resistant uropathogenic Escherichia coli less virulent? J. Infect. Dis. 186:1039-1042.[CrossRef][Medline]
    26. 26
  26. Vogel, T., R. Verreault, M. Gourdeau, M. Morin, L. Grenier-Gosselin, and L. Rochette. 2004. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. Can. Med. Assoc. J. 170:469-473.[Abstract/Free Full Text]
    27. 27
  27. Wang, H., J. L. Dzink-Fox, M. Chen, and S. B. Levy. 2001. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob. Agents Chemother. 45:1515-1521.[Abstract/Free Full Text]
    28. 28
  28. Wang, M. C., C. C. Tseng, C. Y. Chen, J. J. Wu, and J. J. Huang. 2002. The role of bacterial virulence and host factors in patients with Escherichia coli bacteremia who have acute cholangitis or upper urinary tract infection. Clin. Infect. Dis. 35:1161-1166.[CrossRef][Medline]
    29. 29
  29. Warren, J. W., E. Abrutyn, J. R. Hebel, J. R. Johnson, A. J. Schaeffer, W. E. Stamm, et al. 1999. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin. Infect. Dis. 29:745-758.[Medline]
    30. 30
  30. Wullt, B., G. Bergsten, H. Connell, P. Rollano, N. Gebratsedik, L. Hang, and C. Svanborg. 2001. P-fimbriae trigger mucosal responses to Escherichia coli in the human urinary tract. Cell. Microbiol. 3:255-264.[CrossRef][Medline]
    31. 31
  31. Yamamoto, S., A. Terai, K. Yuri, H. Kurazono, Y. Takeda, and O. Yoshida. 1995. Detection of urovirulence factors in Escherichia coli by multiplex polymerase chain reaction. FEMS Immunol. Med. Microbiol. 12:85-90.[CrossRef][Medline]

Journal of Clinical Microbiology, August 2005, p. 4218-4220, Vol. 43, No. 8
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.8.4218-4220.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Ghenghesh, K. S., Elkateb, E., Berbash, N., Abdel Nada, R., Ahmed, S. F., Rahouma, A., Seif-Enasser, N., Elkhabroun, M.-A., Belresh, T., Klena, J. D. (2009). Uropathogens from diabetic patients in Libya: virulence factors and phylogenetic groups of Escherichia coli isolates. J Med Microbiol 58: 1006-1014 [Abstract] [Full Text]  
  • Takahashi, A., Muratani, T., Yasuda, M., Takahashi, S., Monden, K., Ishikawa, K., Kiyota, H., Arakawa, S., Matsumoto, T., Shima, H., Kurazono, H., Yamamoto, S. (2009). Genetic Profiles of Fluoroquinolone-Resistant Escherichia coli Isolates Obtained from Patients with Cystitis: Phylogeny, Virulence Factors, PAIusp Subtypes, and Mutation Patterns. J. Clin. Microbiol. 47: 791-795 [Abstract] [Full Text]  
  • Rijavec, M., Muller-Premru, M., Zakotnik, B., Zgur-Bertok, D. (2008). Virulence factors and biofilm production among Escherichia coli strains causing bacteraemia of urinary tract origin. J Med Microbiol 57: 1329-1334 [Abstract] [Full Text]  
  • Piatti, G., Mannini, A., Balistreri, M., Schito, A. M. (2008). Virulence Factors in Urinary Escherichia coli Strains: Phylogenetic Background and Quinolone and Fluoroquinolone Resistance. J. Clin. Microbiol. 46: 480-487 [Abstract] [Full Text]  
  • Houdouin, V., Bonacorsi, S., Bidet, P., Bingen-Bidois, M., Barraud, D., Bingen, E. (2006). Phylogenetic background and carriage of pathogenicity island-like domains in relation to antibiotic resistance profiles among Escherichia coli urosepsis isolates. J Antimicrob Chemother 58: 748-751 [Abstract] [Full Text]  
  • Johnson, J. R., Drews, S. J., Mazzulli, T., Low, D. E. (2005). Virulence Factors in Escherichia coli. J. Clin. Microbiol. 43: 6221-6222 [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drews, S. J.
Right arrow Articles by Low, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drews, S. J.
Right arrow Articles by Low, D. E.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»